HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro

Participation of p53 protein in the cellular response to DNA damage.

Michael B. Kastan, Onyinye Onyekwere, D Sidransky et al. · PubMed · 1991 · 3.8K citations

Life Sciences, Cell Biology, Molecular Biology +14

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

P. Vasey, Stan B. Kaye, Rachel Morrison et al. · PubMed · 1999 · 691 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy

Hiroshi Maeda · Advanced Drug Delivery Reviews · 2001 · 654 citations

Pharmacy, Medicinal Chemistry, Oncology +14

Dendrimer-platinate: a novel approach to cancer chemotherapy.

N Malik, Evagoras G. Evagorou, Ruth Duncan · PubMed · 1999 · 418 citations

Medicine, Oncology, Pharmacology +11

New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties

Tomáš Etrych, M. Jelı́nková, Blanka Řı́hová et al. · Journal of Controlled Release · 2001 · 335 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14